Obstructive sleep apnea (OSA) is associated with serious comorbid illnesses and diminished quality of life. At this time, continuous positive airway pressure (CPAP) therapy is the treatment of choice. However, only half of those individuals who accept CPAP are still using it at the end of one year. Furthermore, efficacy for improving self-reported sleepiness appears to be greater for patients with severe sleep apnea and severe sleepiness than other patient groups. Some patients, notwithstanding optimized therapy and therapeutic adherence continue experiencing excessive daytime somnolence. Consequently, other treatment modalities have developed, including oral appliances, surgery and pharmacotherapy. It is widely believed, albeit not empirically demonstrated, that an effective medication to treat OSA would elicit better acceptance and adherence than having to use a machine for many hours on a nightly basis. Nonetheless, paucity of data (i.e. lack of large-scale randomized controlled trials), variability of perceived and actual benefits, and adverse side-effects of the drugs thus far tested have prevented the use of pharmacotherapy until now. In this paper we review the outcome data from published trials designed to evaluate efficacy and safety of various medications proposed for treating obstructive sleep apnea.
Introduction
Obstructive sleep apnea (OSA) is a serious, potentially life-threatening condition. It is characterized by repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 s. OSA events are commonly associated with arousals, sleep disruption, and oxygen desaturation. Number of the apneas and hypopneas per hour of sleep (apnea þ hypopnea index or AHI) is commonly used to index OSA severity. Untreated OSA is associated with cognitive impairment, increased risk for motor vehicle accidents, significant comorbidity (hypertension, heart disease and stroke), and impaired quality of life [Deary et al. 2000; Engleman et al. 2000; Nieto et al. 2000; Weiss et al. 1999; Quan et al. 1997; Weaver et al. 1997; Findley et al. 1991] . In the US, symptomatic sleep apnea afflicts an estimated 4 percent of men and 2 percent of women ages 30-70 years [Young et al. 1993 ].
The respiratory events during sleep can be categorized as central, obstructive or mixed. According to the predominance of central vs mixed and obstructive events, OSA is classified as either central or obstructive sleep apnea. A central respiratory event is a reduction in minute ventilation resulting from temporary loss of ventilatory drive to both diaphragm and upper airway dilators. Periodic breathing is a type of central sleep apnea characterized by the alternating pattern of increased ventilation (hyperpnea) and absent or reduced ventilation (apnea or hypopnea). Periodic breathing was described more than a century ago by Cheyne and Stokes (hence called Cheyne-Stokes respiration) in patients with advanced heart failure [Bradley and Floras, 2003; Javaheri, 1996] . Periodic breathing is frequently seen in such patients. By contrast, obstructive sleep apnea is characterized by complete or partial collapse of the upper airway during sleep. Obstructive respiratory events are typically accompanied by vigorous respiratory efforts. A mixed respiratory event consists of an initial period of central apnea followed by an obstructive component.
Continuous positive airway pressure (CPAP) is the first-line standard of care for treating obstructive sleep apnea (OSA). By delivering a fangenerated flow, CPAP maintains airway patency by creating a 'pneumatic splint'. In most patients, CPAP dramatically reduces or eliminates apnea and hypopnea episodes [Mansfield et al. 2004; Tkacova et al. 1998 ]. However, CPAP effectiveness depends directly on patients' utilization of the machine and mask. Overall adherence to CPAP therapy is less than optimal. Generally, 70-75% of patients with OSA accept CPAP. From these, about 40-60% will continue using CPAP for 1 year or longer [Weaver, 2008] , and even fewer use it to the extent prescribed. Thus, nonadherence is a major therapeutic challenge. Proposed alternatives to CPAP include weight loss, oral appliances, surgery and pharmacotherapy.
Notwithstanding positive airway pressure's efficacy for treating sleep-disordered breathing, the search for pharmacotherapy remains competitive and intense. At present, there is no adequately effective drug treatment for sleep apnea. Many substances have been tried clinically and reported with suggestively optimistic findings; however, results of randomized clinical trials are disappointing. The following paragraphs review the major published results.
Methodology
We reviewed the current literature (prior to April 2008) by a Pubmed search using the keywords 'pharmacotherapy', 'medical management' and 'obstructive sleep apnea'. We reviewed the practice guidelines set forth by American Academy of Sleep Medicine [Veasey et al. 2006a ] and also reviewed the Cochrane data base pertaining to medical therapy of obstructive sleep apnea [Smith et al. 2006 ]. We classified the clinical trials as per American Academy of Sleep Medicine Classification of Evidence:
Level I randomized well-designed trials with low alpha and beta errors* Level II randomized trials with high alpha and beta errors* Level III nonrandomized concurrently controlled studies Level IV nonrandomized historically controlled studies Level V case series. *Alpha (type I error) acceptable at 5% or less or p50.05 *Beta (type II error) acceptable beta error of 0.20 (power acceptable at 80-90%).
Pharmacotherapeutic agents

Serotonergic agents
Hypothetically, reduced sleep dependent serotonin delivery to upper airway dilator motor neurons contributes to sleep apnea. Serotonin's effects on upper airway motor neurons and respiratory drive are complex and depend on receptor subtypes. The initial work in this area used animal models. Data indicate serotonin contributes to upper airway patency [Veasey et al. 1996 ]. Further, Veasey and colleagues showed that a serotonergic agent reduced sleep-related breathing events both in rapid eye-movement (REM) and non-REM sleep in an animal model of OSA [Veasey et al. 1999] . Commonly used serotonergic agents and their role for managing OSA are discussed below.
Selective serotonin reuptake inhibitors (SSRIs) Fluoxetine (Prozac Õ , Symbyax Õ ) is the prototype SSRI. Developed and primarily used as an antidepressant, fluoxetine transformed our approach to treating depression and other mood disorders. Other SSRIs were soon to follow [e.g. Paroxetine (Paxil Õ )] Practitioners also use SSRIs to treat other psychiatric conditions, obsessive compulsive disorder, panic disorder and eating disorders (e.g. bulimia and anorexia nervosa). Fluoxetine side-effects include anti-cholinergic (dry mouth, dizziness), psychiatric (nervousness, anxiety and insomnia), CNS (dizziness, asthenia and headache), GI (nausea), and dermatologic (rash and pruritus) effects [Eli Lilly, 2007] . Paroxetine has a similar side-effect profile.
Hanzel and colleagues evaluated fluoxetine's potential medical application for managing OSA. In a prospective open-label crossover efficacy study, the authors compared fluoxetine to protriptyline in twelve patients. They found mean AHI decreased from 57 to 34 episodes per hour with fluoxetine. However, the number and maximum depth of oxygen desaturation did not improve reliably (p40.05) [Hanzel et al. 1991 ].
Berry and coworkers conducted a Sackett level-II evidence based medicine (EBM) double-blind, randomized, placebo-controlled crossover study comparing the acute effects of paroxetine on genioglossus activity in eight patients with OSA. Paroxetine increased peak inspiratory genioglossus activity during NREM sleep but failed to alter AHI [Berry et al. 1999] . Another level-II EBM double-blind, randomized, placebo-controlled crossover study evaluated 20 patients with OSA during 6 weeks of paroxetine administration. Paroxetine reduced apnea index during NREM sleep but not during REM sleep. Furthermore, next-day, self-reported sleepiness and cognitive function failed to improve with treatment [Kraiczi et al. 1999] . Thus, SSRIs are not currently recommended for managing OSA.
Mirtazapine (Remeron Õ ) Mirtazapine is a piperazinoazepine-derivative tetracyclic antidepressant [Organon, 1999] . Mirtazapine has 5HT-2C and 3 antagonist action [Carley et al. 2007; Veasey et al. 2006b ]. It is thought to act as a central ventilatory stimulant by counteracting inhibitory effects of vagal-nucleus solitarius ventilatory input Veasey et al. 2006c . In anesthetized rats, mirtazapine increases genioglossal activity, therefore acting as an upper airway dilator [Berry et al. 2005 ]. This led Carley and associates to test mirtazapine for efficacy in twelve individuals with OSA. A randomized, double-blind, three-way crossover study was performed (15 mg mirtazapine, 4.5 mg mirtazapine, and placebo taken once daily). By the end of one week, mirtazapine reduced AHI by almost 50 percent [Carley et al. 2007 ]. Recently, Marshall and colleagues conducted two randomized placebo controlled clinical trials to evaluate the efficacy of mirtazapine in management of OSA. The medication at various doses failed to improve sleep apnea [Marshall et al. 2008 ]. Mirtazapine's antihistaminergic properties make it sedating and subjects in the above studies gained weight. Such outcomes in patients with OSA, who tend to be sleepy and obese, compromise its use clinically in this population.
REM suppressants
Atonia characterizes REM sleep and thereby interferes with the thoraco-abdominal muscles of respiration. This worsens the respiratory mechanics during REM sleep. During REM sleep an increased number of obstructive apnea and hypopnea events are noticed. Hence it would be reasonable to think of REM suppressants as therapeutic agents for management of OSA. However the effectiveness of REM suppressants in OSA is not determined [Veasey et al. 2006 ]. There is a spectrum of drugs which act as REM suppressants. SSRI (fluoxetine and paroxetine), tricyclic antidepressants [Veasey et al. 2006 ], alcohol, and stimulants (dextroamphetamine and pemoline) have REM-suppressing effects. The role of SSRI in the management of OSA has already been discussed in the previous section.
Protryptiline (Vivactilß) Protryptiline is a tricyclic antidepressant. It has anticholinergic, serotonin and noradrenergic reuptake inhibitory effects. This drug was evaluated in management of OSA due to its REM suppressant property. Hanzel et al. compared the effects of protryptiline to fluoxetine in the treatment of twelve OSA patients in a prospective unblinded crossover study. Protryptiline significantly decreased the AHI from 57 to 33; however there was no decrease in REM AHI. The number of desaturation episodes per hour was not significantly decreased. The improvement in oxygen desaturation from nadir was also not significant [Hanzel et al. 1991] .
Brownell et al. [1982] conducted a double-blind crossover study evaluating the use of protryptiline in five men with OSA. After 2 weeks of treatment a reduction in daytime somnolence and improvement in nocturnal oxygen saturation were reported. REM apnea was reduced with no overall decrease in apnea frequency and duration. As expected, authors reported a decrease in REM stage time. However, the decrease in REM apnea time could be secondary to the decrease in REM stage time. Decreases in REM time, REM apnea duration and improvement in oxygenation persisted after six months of treatment.
In a randomized, double-blinded, placebocontrolled study of protryptiline in ten patients with OSA, no beneficial effect of protriptyline on symptoms or apnea hypopnea indices were found [Whyte et al. 1998 ]. By contrast, in another study, protriptyline in twelve patients with moderateto-severe OSA produced subjective improvement in daytime somnolence, decrease in NREM AHI and a significant reduction in the peak fall in oxygen saturation from 16% to 9%. Anticholinergic side effects such as dry mouth, constipation and urinary hesitancy were noticed [Smith et al. 1983 ]. Thus, protryptiline may reduce AHI and daytime sleepiness; however, the reduction in AHI is not sufficient to warrant using this drug in OSA [Veasey et al. 2006 ].
Clonidine (Catapress Õ ) Clonidine is a noradrenergic alpha 2 agonist and is usually used as an antihypertensive agent. The rationale for evaluating clonidine in OSA stems from its REM suppressant effect. However, clonidine has also been shown to cause collapse of the upper airway in animal studies [O'Halloran et al. 2000 ]. The effect of clonidine was studied in eight patients with OSA in a level III study design. Clonidine at a dose of 0.2 mg for 10 days totally suppressed REM sleep in two patients. In the other six patients there was significant decrease in REM sleep. In six patients there was an improvement in nocturnal hypoxemia. Of these six patients, this effect was due to REM suppressant activity in two patients and improvement of obstruction during unsuppressed REM sleep in rest of them. However in two of the eight subjects clonidine converted their hypopneas into apneas [Issa, 1992] . The major side-effects of clonidine are CNS depressant effects and orthostatic hypotension. Consequently, clonidine is not recommended in the management of OSA.
Ventilatory stimulants
One might intuitively expect ventilatory stimulants to improve sleep-related breathing. Although various drugs have been evaluated, none of them are promising at this time. We will review common drugs in this class with respect to therapeutic potential for treating OSA.
Methylxanthines
Theophylline and aminophylline are drugs in the methylxanthine class, commonly used as bronchodilators for managing asthma and chronic obstructive pulmonary disease (COPD). The mechanism of action involves blocking phosphodiesterase with a resultant increase in cAMP. This in turn stimulates adrenal medullary secretion of epinephrine. Methylxanthines have CNS, respiratory and cardiac stimulatory effects. Owing to its adrenergic activity, arrhythmias are a major adverse side-effect, limiting the use of this class of medications. Seizures are also a worrisome side-effect. These concerns have significantly diminished the use of methylxanthines even in the management of airway diseases.
Espinoza and colleagues studied the effects of acute intravenous administration of aminopohylline in ten patients with OSA in a randomized, placebo-controlled crossover study (level III). They observed aminophylline-related reduction in central apnea and central component of mixed apnea; however, there was no effect on obstructive apnea. They also reported an unfavorable increase in sleep fragmentation and reduction in sleep efficiency [Espinoza et al. 1987 ].
The use of theophylline has been evaluated in various studies. The effect of theophylline was studied initially by Mulloy McNicholas [1992] using a double-blind, placebo-controlled crossover design to assess oral theophylline for 4 weeks in twelve patients with OSA (level II study). They noticed a small but statistically significant reduction in AHI (from 49 to 40 episodes per hour). Oxygen desaturations were less with theophylline but mean overnight oxygen saturation remained unchanged. They also noticed deterioration in sleep quality in patients receiving theophylline. Similarly, another study compared the efficacy of CPAP versus theophylline in patients with OSA (level II study). In this study, a small improvement occurred in both AHI and desaturation index [Saletu et al. 1999] . In a double-blind, placebocontrolled, randomized crossover study of 14 patients with mild OSA, there was again a very small but significant reduction in AHI from 9.2 to 6.7 episodes per hour of sleep (level II study) [Hein et al. 2000] .
Recently a study group led by Orth evaluated oral theophylline's value as an adjunctive therapy to CPAP in 16 patients with mild-to-moderate OSA (mean AI of 12.8 episodes per hour) in a randomized, double-blind crossover study. They used autotitrating CPAP machines to evaluate the effect of theophylline on positive pressure requirements. They saw neither an improvement in AHI nor a reduction in positive pressure requirements. In contrast, they noticed a theophylline-related reduction in total sleep time and sleep efficiency [Orth et al. 2005] . Overall, the utility of theophylline for reducing or treating OSA is marginal and lacks consistency. However, its side-effect profile largely makes this class of drug unsuitable as a viable therapeutic option for managing OSA.
Opioid antagonist -naloxone (Narcan Õ ) Naloxone is an opioid antagonist used primarily to manage opiate overdose. The rationale for trying opioid antagonists is the possible theoretical role that endogenous opiates play in the pathogenesis of sleeps disordered breathing. Naloxone, administered via intravenous infusion was studied in ten obese patients afflicted with sleep apnea (level III). The desaturation index fell by 21 percent in patients who received naloxone [Atkinson et al. 1985] . Other smaller studies found no benefit in OSA [Guilleminault and Hayes, 1983] . Naloxone also reportedly reduces sleep efficiency [Veasey et al. 2006 ] and can provoke acute opioid withdrawal in patients who chronically take opiates. Overall, naloxone has not shown to be of any benefit in the management of OSA.
Doxapram (Dopram Õ ) Doxapram is a respiratory stimulant, available only as an intravenous injection. The need for administration as an intravenous bolus or infusion complicates the logistics of its long-term clinical use. Doxapram is rarely used; use is mostly limited to reducing druginduced CNS depression and treating respiratory depression following anesthesia. Doxapram's respiratory stimulant property raised the possibility for its application in OSA.
There is a single, four-patient study on subjects with obstructive sleep apnea. After an intravenous infusion of doxapram the average oxygen desaturation improved and apnea durations were shorter (level II) [Suratt et al. 1986 ]. AHI was not reported. Doxapram is contraindicated in patients with seizures, cerebrovascular accident, cardiovascular disease, severe hypertension and hyperthyroidism. The side-effect profile and route of administration limits the feasibility of using this drug clinically to treat OSA.
Nicotine is used primarily as a smoking cessation aid. The action of nicotine is complex, with binding at several muscarinic and nicotinic receptor subtypes. Effects are dose-dependent and nicotine has both CNS and respiratory stimulant effects. Studies in cats revealed an excitatory effect on upper airway dilators (e.g. genioglossus) [Haxhiu et al. 1984] .
A case series of eight patients with OSA using nicotine gum revealed a decrease in apnea index from 85 to 62 within 2 h of use [Gothe et al. 1985] . Davila and colleagues evaluated the effect of transdermal nicotine on 20 OSA patients in a randomized double-blind crossover placebo controlled study (level I). They failed to find improvement in AHI but found nicotinerelated total sleep time, sleep efficiency, and REM sleep duration reductions [Davila, 1994] . Zevin and colleagues likewise found no AHI reduction in response to 2 and 4 mg nicotine patches in eleven OSA patients (level II study) using a double-blind, randomized crossover design.
Nicotine has multiple side-effects (including vasospasm) making it unsuitable for administering to patients with coronary disease. Notwithstanding nicotine's respiratory stimulant property, no decrease in AHI was noticed in the abovementioned studies. Consequently, nicotine is not recommended for treating OSA.
Medications to improve nasal patency Sleep-disordered breathing, particularly hypopnea episodes may occur in response to increased upper airway resistance. Therefore, medications improving nasal patency benefit patients with OSA.
Oxymetazoline (Afrin Õ ) Oxymetazoline acts on arterioles in the nasal mucosa and causes vasoconstriction by stimulating alpha-adrenergic receptors. It is available as an over-the-counter medication for temporary relief of nasal congestion. Extended use of this drug causes rebound phenomenon and worsens the congestion.
The use of oxymetazoline in OSA was evaluated in a randomized, controlled study. The authors compared the effects of oxymetazoline, the best sleeping position and the combination of two in 20 OSA patients (mean AHI of 17.5 episodes per hour). They did not find any benefit of oxymetazoline as a single therapy in patients with OSA. There was a small but significant reduction in AHI in the best sleeping position and the combination arms (level II) [Braver and Block, 1994] . As there is no documented benefit of oxymetazoline in OSA and its side-effects, oxymetazoline appears to do more harm than good.
Inhaled corticosteroids (Nasarel Õ , Rhinocort Õ , Aqua Õ , Nasacort Õ ) Inhaled nasal steroids are used as an adjunctive therapy for seasonal or perennial rhinitis. Four weeks of fluticasone nasal spray in snorers with rhinitis were evaluated using a randomized, double blinded, placebocontrolled crossover study on 23 patients. Thirteen had AHI values above ten episodes per hour. Within this sub-population the AHI decreased from 30.3 to 23.3 (p50.05) when fluticasone was used. Fluticasone also reduced nasal airway resistance, nasal congestion and improved daytime alertness. The researchers concluded 'intranasal fluticasone is of benefit to some patients with OSA and rhinitis' (level I) [Kiely et al. 2004 ]. It should be noted that sleep-disordered breathing was not reduced to normal levels; therefore, nasal corticosteroid use is not suitable as an isolated therapy for managing OSA.
Topical lubricant
Surface tension of the upper airway may influence the pathogenesis of OSA mechanically by changing tissue adhesion. Topical lubricants decrease the surface tension and therefore may help counteract airway collapse in patients with OSA. A randomized, double-blinded, placebo-controlled trial evaluating the efficacy of topical lubricants in managing OSA found a 42% decrease in AHI in patients with OSA [Jokic et al. 1998 ]. However, topical lubricants are not recommended as an isolated therapy for OSA.
Oxygen
Intermittent hypoxia is possibly the underlying cause for various systemic ramifications of OSA. For this reason numerous studies sought to evaluate supplemental nocturnal oxygen therapy in patients with OSA. In an early study, Phillips and coworkers compared CPAP efficacy and supplemental nocturnal oxygen therapy in eight mild OSA patients. These patients were given 4 l/min of oxygen for 1 month, followed by air for 1 month, and finally CPAP therapy. At the end of each month, polysomnography was performed. Supplemental oxygen was associated with a significant reduction in hypopneas. There was also a significant improvement in mean low oxygen saturation level when oxygen therapy was compared with baseline and air control condition (level II trial) [Phillips et al. 1990 ].
Transtracheal oxygen, delivered beyond the level of obstruction, has also been assessed in small samples [Farney et al. 1992; Chancey and Aldrich, 1990] . Farney and colleagues compared the use of room air, CPAP, nasal oxygen and transtracheal oxygen. CPAP was the most effective in reducing the AHI. Nasal canula oxygen did not decrease the AHI; however, they found a statistically significant reduction in AHI with transtracheal oxygen delivery (64.6 to 26.2 episodes per hour) [Farney et al. 1992] . A larger study of nasal canula administered oxygen (n ¼ 43 patients with OSA and nocturnal hypoxemia) did not find any decrease in AHI. Oxygen administration improved the minimum nocturnal oxygen saturation, improved daytime symptoms, and significantly decreased Epworth Sleepiness Scale Scores [Lansberg et al. 2001 ] (level III study). As one might suspect, oxygen helps maintain saturation levels but does not improve airway patency, except possibly when administered transtracheally. The latter findings require replication and extension before it can be considered a viable therapeutic mode.
Acetazolamide
Acetazolamide induces metabolic acidosis and augments central respiratory drive. This medication is used to treat some forms of central sleep apnea. Acetazolamide has also been evaluated for efficacy in patients with obstructive and mixed apnea. In this section we will review its use in OSA.
In a randomized, double blinded, placebocontrolled study, Whyte and associates compared the efficacy of acetazolamide and protriptyline, finding reduced apnea/hypopnea frequency but no symptom improvement in the acetazolamide group. Only one patient was able to tolerate the drug in the long run. The major side-effects that led to discontinuation of the drugs were parasthesias and nocturnal enuresis [Whyte et al. 1998 ]. Another study found no benefit with acetazolamide in four patients with OSA [Sharp et al. 1985] but a third study (unblended and uncontrolled) reported small decreases in AI and improved oxygenation in nine patients with OSA [Tojima et al. 1998 ]. These studies were conducted in the 1980s and to our knowledge more recent data are not available. Acetazolamide is not currently recommended for managing OSA.
Physostigmine
In patients with OSA and multisystem atrophy, a decrease in pontine cholinergic projections was found [Gilman et al. 2003 ]. Physostigmine is an acetycholinesterase inhibitor with cholinergic action. This formed a rationale for investigating physostigmine in a randomized, double-blinded, placebo-controlled cross-over study for possible use in managing OSA. Physostigmine infusion for 7 h reduced mean AHI by 21.4% and improved minimum oxygen saturation in ten patients with OSA. Overall, physostigmine was well tolerated. A reduction, however, in total sleep time was noted [Hedner et al. 2003 ]. The role of physostigmine in managing OSA needs further study in a larger and more diverse sample of patients with varying severity of OSA and a spectrum of comorbid conditions.
Modafinil (Provigil Õ )
In a meta-analysis by Patel et al., CPAP improved sleepiness both subjectively and objectively; however, there was significant heterogeneity in Epworth Sleepiness Scale (ESS) improvement. They further noticed that when analysis was restricted to studies of moderate to high quality there was no significant difference in mean ESS score reduction. A greater reduction in ESS was noticed among a subgroup of patients with severe sleep apnea (AHI430) and severe sleepiness(ESS411) when compared with the rest [Patel et al. 2003 ]. Hence CPAP may not be equally efficacious in all subgroups of patients with OSA. It is also widely known through clinical experience that some patients with OSA who are otherwise well treated with positive airway pressure continue to experience residual sleepiness.
Modafinil is a wake-promoting agent approved for treating narcolepsy. The exact mechanism of action is not clear. Current theory ascribes most of its action to central histaminergic activation; however, an intact central alpha adrenergic system seems to be necessary for modafinil to work. Therefore, modafinil was evaluated as a management option for excessive daytime sleepiness in just such a patient group.
In an early study, Arnulf and colleagues studied six patients with OSA using a double-blind, random crossover design. Two weeks treatment with modafinil reduced daytime sleep duration and decreased daytime somnolence. Modafinil did not affect the respiratory events (level II study) [Arnulf et al. 1997 ]. In another study, 30 sleepy patients with adequately CPAP-treated OSA received modafinil or placebo for 2 weeks in a double-blind, randomized crossover study. The study found modafinil-related improvement in alertness measured using the maintenance of wakefulness test but no diminution of sleepiness. They also noted a significant reduction in CPAP use in the patients who received modafinil (level II study) [Kingshott et al. 2001] .
A large-scale, 4-week, randomized, double-blind, placebo-controlled parallel group trial was conducted to evaluate modafinil for treatment of residual sleepiness in OSA patients effectively treated with CPAP. Seventy-seven patients were treated with escalating dose of modafinil (200 mg/d, week 1; 400 mg/d, weeks 2-4) and were compared to a parallel placebo control group. Modafinil significantly improved daytime sleepiness evaluated by Epworth Sleepiness Scale and Multiple Sleep Latency Test (MSLT).
The most common adverse events were headache and nervousness. Additionally, no reduction in CPAP use was found in association with modafinil treatment when compared to placebo [Pack et al. 2001] .
In a 12-week, multicenter, randomized, doubleblind, parallel-group placebo-controlled trial, Black and Hirshkowitz reported modafinilrelated improvement on the Maintenance of Wakefulness Test, Epworth Sleepiness Scale, and ratings of Global Clinical Improvement. No reduction in CPAP use was found (level I study) [Black and Hirshkowitz, 2005] . Furthermore, in the 12-month open-label extension of this study, modafinil continued to maintain improved wakefulness, functional status and quality of life. The most common adverse effects were infection, nervousness and headache. In the entire group, six patients had a significant increase in blood pressure [Hirshkowitz and Black, 2007] .
The combined results from six randomized, double-blind, placebo-controlled trials originally designed to evaluate efficacy and the safety of modafinil in the management of excessive daytime sleepiness were analyzed for adverse events. Patients (n ¼ 1529) suffering from narcolepsy, sleep apnea, and shift work sleep disorder were on modafinil for up to 12 weeks. The most common adverse events were headache, nausea and infection. Notwithstanding concerns regarding blood pressure, only ten patients (51%) had clinically significant increases [Heitmann et al. 1999] . A recent FDA alert regarding possible modafinil-related life-threatening skin reactions was issued [Food and Drug Administation, 2008] . Aftermarket surveillance data found rare cases of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS) and drug rash with eosinophilia and systemic symptoms (DRESS). Psychiatric symptoms, including mania, hallucinations and anxiety, have also been reported. Modafinil is approved to excessive somnolence in adult patients with OSA who are otherwise well treated with positive airway pressure.
Hormonal treatment
Medroxyprogesterone and estrogen therapy The loss of protective effect of estrogen and progesterone are hypothesized to be the cause for increased incidence of OSA in postmenopausal women. Estrogen and progesterone may enhance chemosensitivity and act as ventilatory stimulants. Therefore several studies have explored possible efficacy of these hormones in managing OSA.
Cook and associates studied the effectiveness of medroxyprogesterone in ten men with OSA. A randomized, double-blinded, placebo-controlled crossover study found no alteration in AHI or total sleep time with medroxyprogesterone administered for 1 week (level III study) [Cook et al. 1989 ]. Another randomized, placebo-controlled study evaluating the efficacy of combined estrogen and progesterone in nine healthy women (postmenopausal due to oophrectomy) discovered a significant reduction in AHI (15 to 3 episodes per hour) [Pickett et al. 1989 ]. Improved sleep related breathing was also found in a study of estrogen alone and combination of estrogen and medroxyprogesterone. Using a prospective, crossover inception cohort design of five postmenopausal women, estrogen as an isolated drug as well as in combination with medroxyprogesterone reduced the RDI significantly [Keefe et al. 1999] .
Six postmenopausal women with mild to moderate OSA were studied in a progesterone vs placebo-controlled prospective hormone replacement therapy trial. Patients were given an estrogen patch with placebo followed by estrogen patch with progesterone. Estrogen monotherapy decreased the AHI significantly whereas this benefit was lost when estrogen was combined with progesterone (level II study) [Manber et al. 2003 ].
In another study, neither estrogen alone nor the combination of estrogen and progesterone had any beneficial effect on AHI in 15 postmenopausal women with OSA [Cistulli et al. 1994 ]. Sixty-two postmenopausal women were evaluated for the prevalence of sleep-related breathing disorder and the impact of estrogen replacement therapy. In a randomized, double-blind, placebocontrolled study estrogen replacement therapy had little effect on sleep apnea and no effect on partial upper airway obstruction (level II study) [Polo-Kantola et al. 2003 ].
The role of hormone replacement therapy in 51 postmenopausal women with insomnia was evaluated by Saletu-Zyhlarz and colleagues. In a randomized, double-blind, placebo-controlled three-arm design they compared the effects of estrogen with progesterone, estrogen and placebo. They found a significant reduction in AHI in the arm receiving the combination of estrogen and progesterone when compared with placebo and baseline. Estrogen as a monotherapy did not decrease the AHI. However the baseline AHI was only 7 AE 11 in the study population [Saletu-Zyhlarz et al. 2003 ]. Medroxyprogesterone as treatment for OSA was evaluated in 21 postmenopausal patients using a randomized, placebo-controlled, double-blinded study design. Eleven of these patients were on medroxyprogesterone for 1 month and the only significant finding was a reduction in the maximum duration of apnea (p50.03) [Block et al. 1981] . Overall, due to lack of consistent data showing beneficial effect from hormonal replacement therapy, it is not recommended for management of OSA.
Androgen blocking drugs (Eulexin Õ ) The prevalence of OSA is two to four times higher in men when compared with women [Young et al. 1993] . It is unclear whether this is due to the protective effects of the female sex hormones or the detrimental effect of the male sex hormones. Testosterone administration significantly worsens sleep apnea and duration of nocturnal hypoxia (level II study) [Liu et al. 2003 ]. Androgen blockade with flutamide (evaluated in eight men with sleep apnea) did not produce significant benefit or lower respiratory disturbance index (level III study) [Stewart et al. 1992 ]. As such, there does not appear to be a role for androgen blocking drugs in the medical management of OSA at this time. The multitude of endocrine, metabolic and sexual side-effects would make this class of drugs an unattractive option even if they improved nocturnal breathing.
Thyroxine (Levothroid, Õ Levoxyl, Õ Synthroid, Õ Tirosint, TM Unithroid Õ ) The association between hypothyroidism and OSA has been studied for a long time, especially with the focus on possible symptom overlap between the two conditions. The weight gain from hypothyroidism could potentially worsen sleep apnea. Approximately 1.6-11% of sleep clinic patients have the two disorders together. Skjodt et al. [1999] screened 200 patients with high clinical suspicion of OSA for hypothyroidism. Of the 200 patients, 124 patients were diagnosed with OSA by polysomnography and 3 patients had previously undiagnosed hypothyroidism. Undiagnosed hypothyroidism was seen in 2.4% patients with OSA. They noticed that the sleep disordered breathing, symptoms and nocturnal hypoxia resolved with thyroxin therapy alone.
Rajagopal and colleagues evaluated eleven patients with hypothyroidism. Nine of these patients were found to have OSA with a mean AHI of 71.8. AHI decreased from 71.8 to 12.7 with thyroxin therapy, even without any weight loss [Rajagopal et al. 1984] .
The American Academy of Sleep Medicine practice guidelines state that 'all patients presenting with OSA should be evaluated with a history and physical exam for signs and symptoms of hypothyroidism and treated if clinical suspicion is confirmed with appropriate blood tests'. The guidelines also suggest that due to the possibility of organ ischemia induced by thyroxin replacement in the setting of hypoxia due to OSA, CPAP should be used to alleviate OSA while thyroxin therapy is started [Veasey et al. 2006] Growth hormone Sleep apnea has been reported in patients with acromegaly. According to one study, 8 of 14 patients with acromegaly had sleep apnea. After 6 months of treatment with Sandostatin q monthly they found that the AHI decreased from 29.4 to 13.4 (p50.025) [Ip et al. 2001 ]. Grunstein and associates evaluated 19 patients with acromegaly and OSA and they found a 50% decrease in RDI (p50.0002) after 6 months therapy with octreotide. They also noticed oxygen desaturation and sleepiness improved after treatment with octreotide [Grunstein et al. 1994 ]. The American Academy of Sleep Medicine practice guidelines suggest that 'all patients with OSA should be evaluated by history and physical exam for acromegaly and if suspected appropriate endocrinology work up should be pursued. Treatment of the underlying endocrinological disorder is expected to improve OSA' [Veasey et al. 2006 ].
Summary
Obstructive sleep apnea is a prevalent, chronic condition, involving airway collapse, sleep disturbance, and in many cases, oxyhemoglobin desaturation. OSA is commonly associated with excessive sleepiness, impaired quality of life, and serious comorbid illnesses. Positive airway pressure therapy remains the treatment of choice but requires patient acceptance and hours of nightly use, Consequently, pharmacotherapy is thought to be desirable and is being investigated extensively. To date, a few studies show some improvement in OSA and its symptoms; however, large-scale randomized controlled trials are lacking, results are variable, and side-effect profiles are unfavorable. Nonetheless, a subset of patients may have positive outcomes and further studies are needed to identify the subpopulation of patients with OSA who may benefit from pharmacotherapy. At present, pharmacotherapy for OSA is not of proven benefit. However, pharmacological treatment of residual sleepiness, notwithstanding adequate positive airway pressure therapy delivery and adherence, is indicated and may improve OSA or daytime sleepiness. The use of medications as ancillary treatment for sleepiness among CPAP-treated patients has captured the attention of pharmaceutical developers and we are seeing growing interest in this application. Work is also continuing on serotonin antagonists that are regarded by many as the most fertile ground for finding an OSA drug therapy. Our growing understanding of the role of orexins, histamines and adenosine antagonists in modulating wakefulness may also cast new light on mechanisms underlying sleep, sleep-disordered breathing and sleepiness.
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